PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32202904-10	2020	Results showed that the expression of p-p53, p53, Bax and PUMA was upregulated after CBL0137 administration.	CBLC137	85-92	tumor protein p53	Homo sapiens	40-43	
32202904-10	2020	Results showed that the expression of p-p53, p53, Bax and PUMA was upregulated after CBL0137 administration.	CBLC137	85-92	tumor protein p53	Homo sapiens	45-48	
35323988-2	2022	The curaxin CBL0137 has demonstrated promising antitumour activities in multiple cancers such as glioblastoma, acting through p53 activation, NF-kappaB inhibition and chromatin remodelling.	CBLC137	12-19	tumor protein p53	Homo sapiens	126-129	
35323988-3	2022	In the present study, it was revealed using Annexin-V/7-AAD apoptosis assays that CBL0137 has efficacy across several human acute leukaemia cell lines with wild-type TP53, but sensitivity is reduced in TP53-mutated subtypes.	CBLC137	82-89	tumor protein p53	Homo sapiens	166-170	
35323988-3	2022	In the present study, it was revealed using Annexin-V/7-AAD apoptosis assays that CBL0137 has efficacy across several human acute leukaemia cell lines with wild-type TP53, but sensitivity is reduced in TP53-mutated subtypes.	CBLC137	82-89	tumor protein p53	Homo sapiens	202-206	
35323988-4	2022	A heterozygous TP53 loss-of-function mutation in the KMT2A-AFF1 human RS4;11 cell line was generated, and it was demonstrated that heterozygous TP53 loss-of-function is sufficient to cause a significant reduction in CBL0137 sensitivity.	CBLC137	216-223	tumor protein p53	Homo sapiens	144-148	
35323988-5	2022	To the best of our knowledge, this is the first evidence to suggest a clinically significant role for functional p53 in the efficacy of CBL0137 in acute leukaemia.	CBLC137	136-143	tumor protein p53	Homo sapiens	113-116	
35323988-6	2022	Future CBL0137 clinical trials should include TP53 mutation screening, to establish the clinical relevance of TP53 mutations in CBL0137 efficacy.	CBLC137	128-135	tumor protein p53	Homo sapiens	110-114	
33852836-3	2021	We show that CBL0137 displays profound cytotoxic activity against a panel of patient-derived DIPG cultures by restoring tumor suppressor TP53 and Rb activity.	CBLC137	13-20	tumor protein p53	Homo sapiens	137-141	
27370399-3	2017	One such clinical-stage drug candidate, CBL0137, is a curaxin, small molecules which simultaneously downregulate nuclear factor-kappaB (NF-kB) and activate p53 by inactivating the chromatin remodeling complex, Facilitates Chromatin Transcription (FACT).	CBLC137	40-47	tumor protein p53	Homo sapiens	156-159	
27370399-8	2017	CBL0137 induced loss of chromatin-unbound FACT, activated p53, inhibited NF-kB-dependent transcription, and was toxic to GBM cells.	CBLC137	0-7	tumor protein p53	Homo sapiens	58-61	
35323988-0	2022	TP53 loss-of-function mutations reduce sensitivity of acute leukaemia to the curaxin CBL0137.	CBLC137	85-92	tumor protein p53	Homo sapiens	0-4